Impact of the Geriatric Nutritional Risk Index on In-Hospital Mortality and Length of Hospitalization in Patients with Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction

Susumu Hirose 1, Sakiko Miyazaki 1,*, Shoichi Yatsu 1, Akihiro Sato 1,2, Sayaki Ishiwata 1,2, Hiroki Matsumoto 1, Jun Shibata 1, Azusa Murata 1, Takao Kato 1, Shoko Suda 1, Yuya Matsue 1,2, Masaru Hiki 1, Atsutoshi Takagi 1, Hiroyuki Daida 1 and Takatoshi Kasai 1,2,3

1 Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; s-hirose@juntendo.ac.jp (S.H.); syatsu@juntendo.ac.jp (S.Y.); ak-sato@juntendo.ac.jp (A.S.); s-ishiwata@juntendo.ac.jp (S.I.); hmatsumo@juntendo.ac.jp (H.M.); jshitara@juntendo.ac.jp (J.S.); azmurata@juntendo.ac.jp (A.M.); tkatou@juntendo.ac.jp (T.K.); ssuda@juntendo.ac.jp (S.S.); yuya8950@gmail.com (Y.M.); ma-hiki@juntendo.ac.jp (M.H.); a.taka@juntendo.ac.jp (A.T.); daida@juntendo.ac.jp (H.D.); kasai-t@mx6.nisiq.net (T.K.)

2 Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Ochanomizu KS building #303, 3-3-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

3 Cardiovascular Management and Remote Monitoring, Juntendo University Graduate School of Medicine, Ochanomizu KS building #303, 3-3-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

* Correspondence: smiyaza@juntendo.ac.jp; Tel.: +81-33813-3111

Received: 30 March 2020; Accepted: 16 April 2020; Published: 19 April 2020

Abstract: In patients with heart failure (HF), the impact of the Geriatric Nutritional Risk Index (GNRI) on in-hospital mortality and length of hospital stay remains unclear. We aimed to identify the factors associated with increased in-hospital mortality and longer length of hospital stay considering the GNRI in acute decompensated HF with reduced and preserved ejection fraction (HFrEF and HFpEF, respectively). Patients with acute decompensated HF who were admitted to our institution between 2007 and 2011 were investigated. A total of 451 (201, HFrEF; 250, HFpEF) patients were divided into the following: patients with GNRI < 92 and ≥ 92. In HFrEF, there were no significant differences in in-hospital mortality and length of hospital stay between patients with GNRI < 92 and ≥ 92 (median (interquartile range), 24.0 (23.8) days and 20.0 (15.0) days, respectively, p = 0.32). In HFpEF, despite no differences in in-hospital mortality, patients with GNRI < 92 had significantly longer length of hospital stay than those with GNRI ≥ 92 (median (interquartile range), 20.0 (22.3) days and 17.0 (16.0) days, respectively, p = 0.04). In HFpEF, GNRI < 92, along with lower hemoglobin, higher B-type natriuretic peptide, and elevated C-reactive protein levels, were the independent factors for longer length of hospital stay. Among patients with acute decompensated HF, assessment of nutritional status with GNRI is useful for stratifying patients at high risk for longer length of hospital stay in HFpEF but not in HFrEF. These observations are particularly important when considering the increasing elderly population and prevalence of HFpEF.

Keywords: acute decompensated heart failure; Geriatric Nutritional Risk Index; length of hospital stay; malnutrition

1. Introduction

Despite recent advancements in the treatments for heart failure (HF), HF remains one of the major causes of increased risks of hospitalization and mortality [1]. In Japan, the prevalence of HF...
is increasing [2] in association with an increasing elderly population [3]. Multiple comorbidities are a well-known condition in the elderly population [4] and are generally associated with a greater risk of death and longer length of hospital stay. Certainly, in Japan, hospitalized patients with acute decompensated HF have multiple comorbidities [5–7]; an in-hospital mortality rate of approximately 5%, which remains substantial; and a median length of hospital stay of 14–21 days [5], which is substantially longer than that in any Western and Asian countries in association with a different socialized medical system in Japan [8]. HF with preserved ejection fraction (EF) (HFpEF) is prevalent in elderly HF patients and remains a major concern considering its limited treatment options [9]. Thus, it is important to identify the comorbid conditions or factors on admission that are associated with an increased risk of in-hospital mortality and longer length of hospital stay in patients hospitalized due to acute decompensated HF, specifically patients with HFpEF.

Malnutrition is frequently observed and an important risk factor of poor outcomes in patients with HF [10]. Although no nutritional evaluation method for patients with HF has yet been established, it has been reported that the Geriatric Nutritional Risk Index (GNRI) is useful for predicting the mortality risk of elderly HF patients [11]. The GNRI is a simple and objective nutritional index that uses the ideal body weight ratio and serum albumin, and GNRI < 92 is generally used for evaluating the risk of morbidity and mortality in hospitalized elderly patients [12]. However, the impact of the GNRI on short-term outcomes such as in-hospital mortality and LOHS remain uncertain. In particular, the effects of GNRI on such clinical outcomes in patients with HFpEF, which is assessed separately with HF with reduced EF (HFrEF), are of significant interest.

This study aimed to identify the factors associated with increased in-hospital mortality and longer length of hospital stay by considering the GNRI on admission in acute decompensated HF patients with HFrEF and HFpEF, respectively.

2. Materials and Methods

2.1. Subjects

This was a single-center, retrospective, observational study using a prospective database. The Institutional Review Board of Juntendo University Hospital approved the study protocol, and informed consent was obtained from all patients. Patients who were admitted to the cardiac intensive care unit in Juntendo University Hospital for acute decompensated HF from January 2007 to December 2011 were included in the study. Acute decompensated HF was defined based on the modified Framingham criteria [13]. Patients with acute coronary syndrome, active malignancy, and hemodialysis and patients undergoing surgery during hospitalization were excluded from this study. Additionally, patients who had missing data at baseline were excluded.

2.2. Data Collection

Baseline data were prospectively collected at the time of initial hospital admission. The medical history was obtained from a review of the patients’ clinical charts. Standard two-dimensional echocardiography was performed for each patient. Left ventricular EF (LVEF) was calculated according to the modified Simpson method. In the present study, HFpEF and HFrEF were defined as LVEF ≥ 40% and <40%, respectively [14]. Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation with a Japanese coefficient from baseline serum creatinine levels [15]. GNRI was calculated from the serum albumin and body mass index obtained on hospital admission as follows: 14.89 × serum albumin (g/dL) + 41.7 × body mass index/22 [12]. Low GNRI (<92) was defined as moderate-to-severe nutritional risk, and high GNRI (≥92) was defined as low or no nutritional risk, according to a previous report [12]. The incidence of in-hospital mortality and the date of discharge were prospectively collected. The endpoints of interest were in-hospital mortality and length of hospital stay. To assess the effects of the factors associated with length of
hospital stay separately from in-hospital mortality, patients with in-hospital mortality were excluded from the analysis regarding length of hospital stay.

2.3. Statistical Analyses

Normally and non-normally distributed continuous variables are expressed as mean ± standard deviation and median and interquartile range (IQR), respectively. Continuous variables were compared using the unpaired Student’s t-test or Mann–Whitney U-test when appropriate. Categorical variables are expressed as numbers and percentages, and the chi-squared test or Fisher’s exact test was used for comparisons. Factors associated with in-hospital mortality and length of hospital stay were determined by logistic regression analysis in patients with HFrEF and HFpEF, respectively. In these analyses, C-reactive protein (CRP) levels were treated as categorical variables (i.e., > or ≤1.0 mg/dL) to separate the effects of elevated CRP levels (i.e., >1.0 mg/dL) from subjects with subclinical/healthy CRP levels (≤1.0 mg/dL) [16]. Plasma B-type natriuretic peptide (BNP) was treated as a log-transformed continuous variable because the values were skewed. Furthermore, because of the skewed distribution, length of hospital stay was also used as a categorical variable (i.e., > or ≤ geometric mean of length of hospital stay). Univariate logistic regression analysis was performed by considering the following independent variables: age, sex, history of prior HF, ischemic etiology, atrial fibrillation, diabetes mellitus, hypertension, current smokers, New York Heart Association (NYHA) class ≥ III, serum sodium level, serum potassium level, hemoglobin level, eGFR, elevated CRP level, plasma BNP level, use of medications on admission, and GNRI < 92, in addition to in-hospital mortality or longer hospital stay as dependent variables. Independent variables with p values < 0.15 in the univariate analysis were included in the multivariate analysis. A two-sided p-value < 0.05 was considered statistically significant. All analyses were performed using the EZR version 1.37 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Study Population

A total of 751 patients were admitted to the cardiac intensive care unit due to acute decompensated HF. Patients with acute coronary syndrome and active malignancy, who underwent surgery during hospitalization, and who were on long-term hemodialysis were excluded from the study (n = 190). Additionally, 110 patients whose data for GNRI and/or others were not available at the time of initial hospital admission were excluded from the analysis. Thus, 451 patients, including 201 with HFrEF and 250 with HFpEF, were included in the study (Figure 1). Patients with HFpEF were significantly older than those with HFrEF (71.5 ± 13.1 years versus 67.1 ± 14.3 years, respectively, p < 0.001). However, there were no significant differences in the other variables, including GNRI, between the two groups (GNRI, 93.1 ± 13.6 in HFrEF and 92.3 ± 12.5 in HFpEF, p = 0.51). Overall, in-hospital mortalities were observed in 41 (14 (7.0%) in HFrEF and 27 (10.8%) in HFpEF) patients (9.1%) (p = 0.18). The length of hospital stay in patients without in-hospital mortality was significantly greater in the HFrEF group than in the HFpEF group (median (IQR), 21.0 (18.0) days versus 18.0 (18.5) days, respectively, p = 0.048).
105 patients showed GNRI < 92 (47.8%).

### 3.2. Heart Failure with Reduced Ejection Fraction

#### 3.2.1. Baseline Characteristics

Characteristics of patients with HFrEF (n = 201) are shown in Table 1. Among them, 96 and 105 patients showed GNRI < 92 (47.8%) and GNRI ≥ 92 (52.2%), respectively. Patients with GNRI < 92 were significantly older and had lower hemoglobin levels, higher BNP levels, and lower body mass index, serum albumin levels and GNRI than those with GNRI ≥ 92 (Table 1).

![Flow diagram of this study.](https://example.com/flow-diagram)

**Figure 1.** Flow diagram of this study. A total of 751 patients were admitted to the cardiac intensive care unit due to acute decompensated heart failure. Among these, 190 patients who had acute coronary syndrome and/or had undergone cardiac surgery, who had malignancy, and who were on hemodialysis were initially excluded, as were 110 patients who had missing data. The 451 eligible patients were subsequently divided into the HFrEF and HFpEF groups. Abbreviations: HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

### Table 1. Characteristics of patients with HFrEF

|                          | Total (n = 201) | GNRI < 92 (n = 96) | GNRI ≥ 92 (n = 105) | p     |
|--------------------------|-----------------|--------------------|---------------------|-------|
| Age, years               | 67.1 ± 14.3     | 71.0 ± 12.0        | 63.6 ± 15.3         | <0.01 |
| Male sex                 | 142 (70.7)      | 66 (68.8)          | 76 (72.4)           | 0.64  |
| Body mass index, kg/m²   | 23.0 ± 5.2      | 20.5 ± 3.4         | 25.2 ± 5.6          | <0.01 |
| Current smoker           | 104 (51.7)      | 54 (56.2)          | 50 (47.6)           | 0.26  |
| Hypertension             | 141 (70.2)      | 65 (67.7)          | 76 (72.4)           | 0.54  |
| Diabetes mellitus        | 76 (37.8)       | 40 (41.7)          | 36 (34.3)           | 0.31  |
| Ischemic etiology        | 88 (43.8)       | 46 (47.9)          | 42 (40.0)           | 0.32  |
| Atrial fibrillation      | 65 (32.3)       | 30 (31.2)          | 35 (33.3)           | 0.77  |
| Prior HF hospitalization  | 111 (55.2)      | 51 (53.1)          | 60 (57.1)           | 0.57  |
| LVEF, %                  | 27.1 ± 6.9      | 27.1 ± 7.1         | 27.0 ± 6.8          | 0.87  |
| NYHA class ≥ III         | 175 (87.6)      | 85 (88.5)          | 90 (85.7)           | 0.68  |
| Serum albumin, mg/dL     | 3.3 ± 0.8       | 2.9 ± 0.5          | 3.7 ± 0.4           | <0.01 |
| Serum sodium, mmol/L     | 138.8 ± 4.2     | 138.2 ± 4.3        | 138.9 ± 4.1         | 0.27  |
| Serum potassium, mmol/L  | 4.2 ± 0.6       | 4.3 ± 0.8          | 4.2 ± 0.5           | 0.33  |
| Hemoglobin, g/dL         | 13.0 ± 2.6      | 12.4 ± 2.6         | 13.5 ± 2.4          | <0.01 |
| eGFR, mL/min/1.73 m²     | 54.5 ± 26.2     | 52.0 ± 27.2        | 56.7 ± 25.1         | 0.20  |
| BNP, pg/dL               | 1106.3 (770.0)  | 1269.4 (893.6)     | 950.0 (683.6)       | <0.01 |
| CRP, mg/dL               | 3.5 (0.9)       | 4.1 (1.0)          | 3.0 (0.9)           | 0.21  |
| Elevated CRP             | 91 (45.3)       | 45 (46.9)          | 46 (43.8)           | 0.88  |
| GNRI                     | 93.1 ± 13.6     | 82.2 ± 6.7         | 103.1 ± 10.3        | <0.01 |
According to the multivariate analysis, only serum sodium and hemoglobin levels were determined as factors associated with longer length of hospital stay (i.e., multivariate analysis, NYHA class level, and low serum sodium, hemoglobin, and eGFR levels showed values < 0.15. According to the multivariate analysis, only serum sodium and hemoglobin levels were determined as independent factors associated with increased in-hospital mortality (Table 2).

### Table 2. Univariate and multivariate analyses of factors associated with increased in-hospital mortality in patients with HFrEF.

| Variables                              | Univariate | Multivariate |
|----------------------------------------|------------|--------------|
|                                        | OR  | 95% CI  | p   | OR  | 95% CI  | p   |
| GNRI < 92 (yes)                        | 2.94 | 0.89–9.70 | 0.08 | -   | -        | -   |
| Diuretics (yes)                        | 2.57 | 0.83–7.97 | 0.10 | -   | -        | -   |
| Serum sodium (1 mmol/L increase)       | 0.79 | 0.70–0.89 | <0.01| 0.81| 0.71–0.91| <0.01|
| Hemoglobin (1 g/dL increase)           | 0.74 | 0.59–0.93 | <0.01| 0.78| 0.61–1.00| 0.04|

CI, confidence interval; GNRI, Geriatric Nutritional Risk Index; HFrEF, heart failure with reduced ejection fraction; OR, odds ratio.

#### 3.2.3. Length of Hospital Stay

There was no significant difference (p = 0.32) in the length of hospital stay between patients with GNRI < 92 and ≥ 92 (median (IQR), 24.0 (23.8) days and 20.0 (15.0) days, respectively) (Figure 2). According to the univariate logistic regression analyses, GNRI < 92, NYHA class ≥ III, high potassium level, and low serum sodium, hemoglobin, and eGFR levels showed p values < 0.15. According to the multivariate analysis, NYHA class ≥ III and serum sodium level were determined as independent factors associated with longer length of hospital stay (i.e., >22 days) (Table 3).

![Figure 2](image-url)
Table 3. Univariate and multivariate analyses of factors associated with length of hospital stay in HFrEF.

| Variables                                | Univariate | Multivariate |
|-------------------------------------------|------------|--------------|
|                                           | OR         | 95% CI       | p   | OR         | 95% CI       | p   |
| GNRI < 92 (yes)                           | 1.62       | 0.91–2.88    | 0.11| -          | -            | -   |
| NYHA class ≥ III (yes)                    | 5.32       | 1.74–16.2    | <0.01| 4.83       | 1.57–14.9    | <0.01|
| Serum potassium (1 mmol/L increase)       | 1.76       | 1.03–2.99    | 0.04| -          | -            | -   |
| Serum sodium (1 mmol/L increase)          | 0.89       | 0.82–0.97    | <0.01| 0.90       | 0.83–0.98    | 0.01|
| Hemoglobin (1 g/dL increase)              | 0.84       | 0.74–0.94    | <0.01| -          | -            | -   |
| eGFR (1 mL/min/1.73 m² increase)          | 0.99       | 0.98–1.00    | 0.10| -          | -            | -   |

CI, confidence interval; eGFR, estimated glomerular filtration rate; GNRI, Geriatric Nutritional Risk Index; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; OR, odds ratio.

3.3. Heart Failure with Preserved Ejection Fraction

3.3.1. Baseline Characteristics

Characteristics of patients with HFrEF (n = 250) are shown in Table 4. Among them, 120 and 130 patients showed GNRI < 92 (48.0%) and GNRI ≥ 92 (52.0%), respectively. Patients with GNRI < 92 were significantly older and had lower body mass index, serum albumin level and GNRI than those with GNRI ≥ 92 (Table 4).

Table 4. Characteristics of patients with HFrEF.

| Variables                                | Total (n = 250) | GNRI < 92 (n = 120) | GNRI ≥ 92 (n = 130) | p   |
|-------------------------------------------|-----------------|---------------------|---------------------|-----|
| Age, years                                | 71.5 ± 13.1     | 74.1 ± 12.6         | 69.0 ± 13.3         | <0.01|
| Male sex                                  | 154 (61.6)      | 71 (59.2)           | 83 (63.8)           | 0.51 |
| Body mass index, kg/m²                    | 22.8 ± 4.4      | 20.2 ± 3.1          | 25.2 ± 4.2          | <0.01|
| Current smoker                            | 108 (43.2)      | 53 (44.2)           | 55 (42.3)           | 0.80 |
| Hypertension                              | 195 (78.0)      | 90 (75.0)           | 105 (80.8)          | 0.29 |
| Diabetes mellitus                         | 102 (40.8)      | 45 (37.5)           | 57 (43.8)           | 0.37 |
| Ischemic etiology                         | 92 (36.8)       | 41 (34.2)           | 51 (39.2)           | 0.43 |
| Atrial fibrillation                       | 96 (38.4)       | 45 (37.5)           | 51 (39.2)           | 0.80 |
| Prior HF hospitalization                   | 134 (53.6)      | 66 (55.0)           | 68 (52.3)           | 0.70 |
| LVEF, %                                   | 56.0 (38.4)     | 55.6 (11.6)         | 56.3 (11.1)         | 0.67 |
| NYHA class ≥ III                          | 202 (80.8)      | 97 (80.8)           | 105 (80.8)          | 1.00 |
| Serum creatinine, mg/dL                   | 1.3 ± 1.0       | 1.4 ± 1.2           | 1.2 ± 0.8           | 0.11 |
| Serum albumin, mg/dL                      | 3.3 ± 0.6       | 2.9 ± 0.5           | 3.6 ± 0.5           | <0.01|
| Serum potassium, mmol/L                   | 4.2 ± 0.7       | 4.2 ± 0.7           | 4.2 ± 0.7           | 0.92 |
| Serum sodium, mmol/L                      | 138.8 ± 4.2     | 138.4 ± 4.3         | 139.1 ± 4.2         | 0.22 |
| Hemoglobin, g/dL                          | 11.9 ± 2.5      | 11.7 ± 2.4          | 12.1 ± 2.5          | 0.20 |
| eGFR, mL/min/1.73 m²                       | 53.7 ± 27.4     | 53.3 ± 30.9         | 54.1 ± 23.8         | 0.80 |
| BNP, pg/dL                                | 757.9 (517.6)   | 820.0 (553.6)       | 706.0 (462.9)       | 0.10 |
| CRP, mg/dL                                | 3.3 (0.9)       | 3.8 (0.9)           | 2.9 (0.7)           | 0.15 |
| Elevated CRP                              | 109 (43.6)      | 55 (45.8)           | 54 (41.5)           | 0.21 |
| GNRI                                      | 92.3 ± 12.5     | 82.0 ± 7.1          | 101.8 ± 8.2         | <0.01|

Variables are expressed as mean ± standard deviation, median, or number (%). ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; GNRI, Geriatric Nutritional Risk Index; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
3.3.2. In-Hospital Mortality

Of the 27 in-hospital mortalities, 16 (13.3%) were observed in patients with GNRI < 92 and 11 (8.5%) in patients with GNRI ≥ 92 (p = 0.23). According to the univariate logistic regression analyses, age, presence of diabetes, presence of atrial fibrillation, prior HF hospitalization, and low serum sodium, hemoglobin, and eGFR levels showed p values < 0.15. According to the multivariate analysis, prior HF hospitalization and eGFR levels were determined as independent factors associated with in-hospital mortality (Table 5).

Table 5. Univariate and multivariate analyses of factors associated with increased in-hospital mortality in HFrEF.

| Variables                               | Univariate | Multivariate |
|-----------------------------------------|------------|--------------|
|                                         | OR 95% CI  | p  | OR 95% CI  | p  |
| Age (1-year increase)                   | 1.04 1.00–1.08 | 0.03 | - | - |
| Diabetes mellitus (yes)                 | 2.32 1.03–5.23 | 0.04 | - | - |
| Atrial fibrillation (yes)               | 0.42 0.16–1.09 | 0.07 | - | - |
| Prior HF hospitalization (yes)          | 3.41 1.32–8.77 | 0.01 | 3.10 | 1.19–8.10 | 0.02 |
| Serum sodium (1 mmol/L increase)        | 0.91 0.84–1.00 | 0.04 | - | - |
| Hemoglobin (1 g/dL increase)            | 0.78 0.65–0.93 | <0.01 | - | - |
| eGFR (1 mL/min/1.73 m² increase)        | 0.97 0.96–0.99 | <0.01 | 0.97 | 0.96–0.99 | <0.01 |

CI, confidence interval; eGFR, estimated glomerular filtration rate; GNRI, Geriatric Nutritional Risk Index; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; OR, odds ratio.

3.3.3. Length of Hospital Stay

Patients with GNRI < 92 had longer length of hospital stay than those with GNRI ≥ 92 (median (IQR), 20.0 (22.3) days and 17.0 (16.0) days, respectively; p = 0.04) (Figure 3). According to the univariate logistic regression analyses, GNRI < 92, male sex, presence of hypertension, ischemic etiology, use of diuretics, low serum potassium and hemoglobin levels, elevated CRP levels, and increased BNP levels showed p-values < 0.15. According to the multivariate analysis, GNRI < 92 and hemoglobin, BNP, and CRP levels were determined as independent factors associated with longer length of hospital stay (i.e., >19 days) (Table 6).

![Figure 3](image-url)  
Figure 3. Comparison of length of hospital stay between patients with GNRI < 92 and ≥92 in HFrEF. Patients with GNRI < 92 showed longer length of hospital stay than those with GNRI ≥ 92. Mann–Whitney U-test was used for comparison between the two groups. Abbreviations: GNRI, Geriatric Nutritional Risk Index; HFrEF, heart failure with reduced ejection fraction.
Table 6. Univariate and multivariate analyses of factors associated with longer length of hospital stay in HFpEF.

| Variables | Univariate | Multivariate |
|-----------|------------|--------------|
| | OR  | 95% CI   | p   | OR  | 95% CI   | p   |
| Male sex  | 0.66 | 0.38–1.14 | 0.14 |  |  |  |
| GNRI < 92 (yes) | 1.71 | 1.01–2.92 | <0.05 | 1.91 | 1.00–3.65 | <0.05 |
| Hypertension (yes) | 0.50 | 0.27–0.95 | 0.04 |  |  |  |
| Ischemic etiology (yes) | 0.55 | 0.31–0.97 | 0.04 |  |  |  |
| Diuretics (yes) | 1.56 | 0.09–2.70 | 0.11 |  |  |  |
| Serum potassium (1 mmol/L increase) | 0.72 | 0.48–1.08 | 0.12 |  |  |  |
| Hemoglobin (1 g/dL increase) | 0.84 | 0.74–0.94 | <0.01 | 0.83 | 0.72–0.95 | <0.01 |
| Log-transformed BNP (1 pg/dL increase) | 2.57 | 1.36–4.85 | <0.01 | 2.06 | 1.03–4.12 | 0.04 |
| Elevated CRP (yes) | 2.85 | 1.62–5.01 | <0.01 | 3.03 | 1.59–5.78 | <0.01 |

BNP, B-type natriuretic protein; CI, confidence interval; CRP, C-reactive protein; GNRI, Geriatric Nutritional Risk Index; HFpEF, heart failure with preserved ejection fraction; OR, odds ratio.

4. Discussion

In this study, several important findings were reported that provide insight into the association between nutritional status on admission and short-term outcomes in hospitalized patients with acute decompensated HF, specifically patients with HFpEF. First, in HFrEF, although serum sodium and hemoglobin levels were identified as independent factors associated with increased in-hospital mortality, there was no association between malnutrition expressed as GNRI < 92 and in-hospital mortality. Second, only serum sodium level was the independent factor associated with longer length of hospital stay, and no association was observed between malnutrition expressed as GNRI < 92 and length of hospital stay in patients with HFrEF. Third, in HFpEF, patients with history of prior HF hospitalization and patients with lower eGFR levels were likely to experience in-hospital mortality, but malnutrition expressed as GNRI < 92 was not a factor associated with increased in-hospital mortality. Finally, in HFpEF, GNRI < 92 was significantly associated with longer length of hospital stay and lower hemoglobin, higher BNP, and elevated CRP levels among patients hospitalized due to acute compensated HF. Our findings suggest that nutritional status on admission assessed using the GNRI may be an important factor when stratifying patients at high risk for longer length of hospital stay in patients hospitalized due to acute decompensated HF, and this should be emphasized in patients with HFpEF.

Previous studies have reported that body mass index and serum albumin levels, which are traditional indicators of nutritional status, can predict mortality in patients with HF [17–19]. Additionally, more recently, some other indices that were basically computed by serum albumin level and lymphocyte count, such as the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score, have also been shown to have prognostic value in patients with HF, and more precisely assessed the prognostic values of malnutrition on long-term clinical outcomes in patients with HF [20,21]. These studies suggest that assessment of nutritional status is important in patients with stable HF. Additionally, a previous study has reported that in patients hospitalized due to acute decompensated HF, either a severe CONUT score or low PNI was associated with an increased risk of in-hospital mortality and prolonged length of hospital stay [22]. Thus, rapid assessment of nutritional status on admission is also important in patients hospitalized due to acute decompensated HF to stratify patients with high risks for in-hospital mortality and prolonged length of hospital stay. The GNRI, which comprises serum albumin level and ideal body weight, is a simpler index used to assess nutritional status than PNI or CONUT, considering that lymphocyte count is not assessed in the GNRI. It has been reported that the GNRI had the greatest incremental value in predicting the risk of poor prognosis in HF outpatients among the three scoring systems [23]. Although the clinical utility of the GNRI for predicting long-term mortality in patients with HF has already been reported in several studies [11,24,25], the association between GNRI and in-hospital mortality or length of hospital
stay has rarely been investigated. In one study by Aziz and colleagues, nutritional status assessed by the Nutritional Risk Index, which also comprises serum albumin level and ideal body weight, was associated with prolonged length of hospital stay [26]. However, there are no studies investigating the impact of malnutrition expressed using GNRI on in-hospital mortality and length of hospital stay in patients hospitalized due to acute decompensated HF separately with HFrEF and HFpEF.

In a recent study by Nishino et al., serum albumin levels on admission were associated with prolonged length of hospital stay [27]. Thus, a novel observation of the present study is that in patients hospitalized due to acute decompensated HF, admission malnutrition based on the GNRI, which can more precisely assess nutritional status compared to other scoring systems, is associated with length of hospital stay in HFpEF but not in HFrEF. Although it is unclear why the GNRI failed to show a statistically significant relationship with either in-hospital mortality or length of hospital stay in patients with HFrEF, age difference may play an important role, as patients with HFrEF are younger than those with HFpEF. According to the Organization for Economic and Cooperation and Development report in 2017, the average length of hospital stay is markedly longer in Japan than in other countries. For patients with HF, a longer hospital stay is a serious problem considering that it negatively affects the patients’ quality of life and increases the patients’ healthcare costs [8]. Furthermore, HFpEF has recently become highly prevalent in patients hospitalized due to acute decompensated HF, possibly as a result of an increasing elderly population [28]. Thus, shortening the length of hospital stay for patients with acute decompensated HF and HFpEF is significantly required. Considering the fact that there are no established pharmacological treatments to improve clinical outcomes of HFpEF and that a more comprehensive approach might be necessary to improve the clinical outcomes of HFpEF [29], it may be worthwhile to investigate whether rapid nutritional intervention can shorten length of hospital stay in elderly patients with HFpEF and malnutrition.

The present study has several limitations. First, because it was an observational study, the results do not confirm the cause-and-effect relationship between malnutrition assessed by the GNRI and in-hospital mortality or length of hospital stay. Thus, further interventional studies are required to confirm this cause-and-effect relationship. Second, in patients with HF, both serum albumin level and body weight are influenced by non-nutritional factors such as fluid overload. Therefore, the measurement of albumin, body mass index, and body weight individually is unsuitable for nutritional assessment in patients with acute decompensated HF. Although using the GNRI as a nutritional indicator may overcome the individual limitations of each indicator [26], the association between the changes in each indicator during hospitalization and clinical outcomes should be assessed in a further study. Third, this study was a single-center, observational study and included a limited number of in-hospital mortalities. Finally, we cannot exclude the possibility that unmeasured factors may have influenced some of our findings, even after taking confounding factors into account. Thus, the findings of our study should be interpreted with caution.

5. Conclusions

Among patients hospitalized due to acute decompensated HF, an assessment of nutritional status on admission by GNRI was not a significant independent factor associated with increased in-hospital mortality, either in patients with HFpEF or HFrEF. Only in patients with HFpEF, GNRI <92, along with lower hemoglobin, higher BNP, and elevated CRP levels was the independent factors for longer length of hospital stay. GNRI is useful for stratifying patients at high risk for longer length of hospital stay in HFpEF but not in HFrEF. These observations provide important information, specifically when we consider an increasing elderly population [3] and its associated increasing prevalence of HF [2], particularly HFpEF.
Author Contributions: Conceptualization, S.H. and S.M.; methodology, S.M., S.S. and T.K. (Takatoshi Kasai); formal analysis, S.H., S.Y., and H.M.; data curation, S.Y., A.S., S.I., J.S., A.M., T.K. (Takao Kato), and M.H.; writing—original draft preparation, S.H.; writing—review and editing, S.M., Y.M., and T.K. (Takatoshi Kasai); supervision, A.T., H.D. and T.K. (Takatoshi Kasai); funding acquisition, T.K. (Takao Kato) and T.K. (Takatoshi Kasai). All authors have read and agreed to the published version of the manuscript.

Funding: This study was partly supported by a JSPS KAKENHI Grant Number JP17K09527, by a Grant-in-Aid for Early Career Scientists Grant Number 18K15904, and by the Juntendo University Young Investigator Joint Project Award 2019-27. These funding sources have no other roles in this study.

Conflicts of Interest: S.H. is an employee of Pfizer Inc. Takatoshi Kasai, S.I., and A.S. are affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi. Takatoshi Kasai is affiliated with a department endowed by Paramount Bed. H.D. received manuscript fees, research funds, and scholarship funds from Kirin Co. Ltd., Kaken Pharmaceutical Co., Ltd., Abbott Japan Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boston Scientific Japan K.K., Bristol-Myers Squibb, Daiichi Sankyo Company, MSD K.K., Pfizer Inc., Philips Respironics, Sanofi K.K., and Takeda Pharmaceutical Co. Ltd. The other authors report no conflicts of interest.

References

1. Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 2009, 53, 1–90.

2. Okura, Y.; Ramadan, M.M.; Ohno, Y.; Mitsuma, W.; Tanaka, K.; Ito, M.; Suzuki, K.; Tanabe, N.; Kodama, M.; Aizawa, Y. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ. J. 2008, 72, 489–491. [CrossRef] [PubMed]

3. Arai, H.; Ouchi, Y.; Toba, K.; Endo, T.; Shimokado, K.; Tsubota, K.; Matsuo, S.; Mori, H.; Yumura, W.; Yokode, M.; et al. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Geriatr. Gerontol. Int. 2015, 15, 673–687. [CrossRef] [PubMed]

4. Nojiri, S.; Itoh, H.; Kasai, T.; Fujibayashi, K.; Saito, T.; Hiratsuka, Y.; Okuzawa, A.; Naito, T.; Yokoyama, K.; Daida, H. Comorbidity status in hospitalized elderly in Japan: Analysis from National Database of Health Insurance Claims and Specific Health Checkups. Sci. Rep. 2019, 9, 20237. [CrossRef] [PubMed]

5. Shiraishi, Y.; Koshaka, S.; Sato, N.; Takano, T.; Kitai, T.; Yoshikawa, T.; Matsue, Y. 9-year trend in the management of acute heart failure in Japan: A report from the National Consortium of Acute Heart Failure Registries. J. Am. Heart Assoc. 2018, 7, e008687. [CrossRef] [PubMed]

6. Yatsu, S.; Kasai, T.; Suda, S.; Matsumoto, H.; Shiroshita, N.; Kato, M.; Kawana, F.; Murata, A.; Kato, T.; Hiki, M.; et al. Impact on clinical outcomes of periodic leg movements during sleep in hospitalized patients following acute decompensated heart failure. Circ. J. 2017, 81, 495–500. [CrossRef]

7. Suda, S.; Kasai, T.; Matsumoto, H.; Shiroshita, N.; Kato, M.; Kawana, F.; Yatsu, S.; Murata, A.; Kato, T.; Hiki, M.; et al. Prevalence and clinical correlates of sleep-disordered breathing in patients hospitalized with acute decompensated heart failure. Can. J. Cardiol. 2018, 34, 784–790. [CrossRef]

8. Ambrosy, A.P.; Fonarow, G.C.; Butler, J.; Chioncel, O.; Greene, S.J.; Vaduganathan, M.; Nodari, S.; Lam, C.S.P.; Sato, N.; Shah, A.N.; et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J. Am. Coll. Cardiol. 2014, 63, 1123–1133. [CrossRef]

9. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200.

10. Lin, H.; Zhang, H.; Lin, Z.; Li, X.; Kong, X.; Sun, G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev. 2016, 21, 549–565. [CrossRef]

11. Honda, Y.; Nagai, T.; Iwakami, N.; Sugano, Y.; Honda, S.; Okada, A.; Asaumi, Y.; Aiba, T.; Noguchi, T.; Kusano, K.; et al. Usefulness of Geriatric Nutritional Risk Index for assessing nutritional status and its prognostic impact in patients aged ≥65 years with acute heart failure. Am. J. Cardiol. 2016, 118, 550–555. [CrossRef] [PubMed]
12. Bouillanne, O.; Morineau, G.; Dupont, C.; Coulombel, I.; Vincent, J.P.; Nicolis, I.; Benazeth, S.; Cynober, L.; Aussel, C. Geriatric Nutritional Risk Index: A new index for evaluating at-risk elderly medical patients. *Am. J. Clin. Nutr.* 2005, 82, 777–783. [CrossRef] [PubMed]

13. McKee, P.A.; Castelli, W.P.; McNamara, P.M.; Kannel, W.B. The natural history of congestive heart failure: The Framingham study. *N. Engl. J. Med.* 1971, 285, 1441–1446. [CrossRef] [PubMed]

14. Yusuf, S.; Pfeffer, M.A.; Swedberg, K.; Granger, C.B.; Held, P.; McMurray, J.J.; Michelson, E.L.; Olofsson, B.; Ostergren, J.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. *Lancet* 2003, 362, 777–781. [CrossRef]

15. Matsuo, S.; Imai, E.; Horio, M.; Yasuda, Y.; Tomita, K.; Nitta, K.; Yamagata, K.; Tomino, Y.; Yokoyama, H.; Hishida, A.; et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am. J. Kidney Dis.* 2009, 53, 982–992. [CrossRef]

16. Mac Giollabhui, N.; Ellman, L.M.; Coe, C.L.; Byrne, M.L.; Abramson, L.Y.; Alloy, L.B. To exclude or not to exclude: Considerations and recommendations for C-reactive protein values higher than 10 mg/L. *Brain Behav. Immun.* 2020, in press. [CrossRef]

17. Horwich, T.B.; Kalantar-Zadeh, K.; MacLellan, R.W.; Fonarow, G.C. Albumin levels predict survival in patients with systolic heart failure. *Am. Heart J.* 2008, 155, 883–889. [CrossRef]

18. Liu, M.; Chan, C.P.; Yan, B.P.; Zhang, Q.; Lam, Y.Y.; Li, R.J.; Sanderson, J.E.; Coats, A.J.; Sun, J.P.; Yip, G.W.; et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. *Eur. J. Heart Fail.* 2012, 14, 39–44. [CrossRef]

19. Shah, R.; Gayat, E.; Januzzi, J.L., Jr.; Sato, N.; Cohen-Solal, A.; diSomma, S.; Fairman, E.; Harjola, V.P.; Ishihara, S.; Lassus, J.; et al. Body mass index and mortality in acutely decompensated heart failure worldwide: A global obesity paradox. *J. Am. Coll. Cardiol.* 2014, 63, 778–785. [CrossRef]

20. Cheng, Y.L.; Sung, S.H.; Cheng, H.M.; Hsu, P.F.; Guo, C.Y.; Yu, W.C.; Chen, C.H. Prognostic nutritional index and the risk of mortality in patients with acute heart failure. *J. Am. Heart Assoc.* 2017, 6, e004876. [CrossRef]

21. Ikawa, T.; Furukawa, T.A.; Sugano, Y.; Honda, S.; Okada, A.; Asaumi, Y.; Aiba, T.; Noguchi, T.; Kusano, K.; et al. Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. *Int. J. Cardiol.* 2017, 230, 529–536. [CrossRef] [PubMed]

22. Shirakabe, A.; Hata, N.; Kobayashi, N.; Okazaki, H.; Matsushita, M.; Shibata, Y.; Nishigoori, S.; Uchiyama, S.; Asai, K.; Shimizu, W. The prognostic impact of malnutrition in patients with severely decompensated acute heart failure, as assessed using the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score. *Heart Vessel.* 2018, 33, 134–144. [CrossRef] [PubMed]

23. Szé, S.; Pellicori, P.; Kazmi, S.; Rigby, A.; Cleland, J.G.F.; Wong, K.; Clark, A.L. Prevalence and prognostic significance of malnutrition using 3 scoring systems among outpatients with heart failure: A comparison with body mass index. *JACC Heart Fail.* 2018, 6, 476–486. [CrossRef]

24. Kinugasa, Y.; Kato, M.; Sugihara, S.; Hirai, M.; Yamada, K.; Yanagihara, K.; Yamamoto, K. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. *Circ. J.* 2013, 77, 705–711. [CrossRef] [PubMed]

25. Yoshihisa, A.; Kanno, Y.; Watanabe, S.; Yokokawa, T.; Abe, S.; Miyata, M.; Sato, T.; Suzuki, S.; Oikawa, M.; Kobayashi, A.; et al. Impact of nutritional indices on mortality in patients with heart failure. *Open Heart* 2018, 5, e002370. [CrossRef] [PubMed]

26. Aziz, E.F.; Javed, F.; Pratap, B.; Musat, D.; Nader, A.; Pulimi, S.; Alivar, C.L.; Herzog, E.; Kukin, M.L. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: An ACAP-HF data analysis. *Heart Int.* 2011, 6, e2. [CrossRef]

27. Nishino, M.; Matsuhiro, Y.; Nakamura, H.; Yasumoto, K.; Yamamura, K.; Tanaka, A.; Matsuaga-Lee, Y.; Nakamura, D.; Yano, M.; Yamato, M.; et al. Which factors are associated with length of stay in older patients with acute decompensated heart failure with preserved ejection fraction?: AURORA study. *Geriatr. Gerontol. Int.* 2019, 19, 1084–1087. [CrossRef]
28. Goyal, P.; Almarzooq, Z.I.; Horn, E.M.; Karas, M.G.; Sobol, I.; Swaminathan, R.V.; Feldman, D.N.; Minutello, R.M.; Singh, H.S.; Bergman, G.W.; et al. Characteristics of hospitalizations for heart failure with preserved ejection fraction. *Am. J. Med.* 2016, 129, 635.e15–635.e26. [CrossRef]

29. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr.; Colvin, M.M.; Drazner, M.H.; Filippatos, G.S.; Fonarow, G.C.; Givertz, M.M.; et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation* 2017, 136, e137–e161.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).